Bas Groot Koerkamp

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8099253/publications.pdf Version: 2024-02-01

		17440	24982
316	15,617	63	109
papers	citations	h-index	g-index
324	324	324	11712
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Outcomes of a Multicenter Training Program in Robotic Pancreatoduodenectomy (LAELAPS-3). Annals of Surgery, 2022, 276, e886-e895.	4.2	57
2	Long-term yield of pancreatic cancer surveillance in high-risk individuals. Gut, 2022, 71, 1152-1160.	12.1	84
3	Impact of nationwide centralization of oesophageal, gastric, and pancreatic surgery on travel distance and experienced burden in the Netherlands. European Journal of Surgical Oncology, 2022, 48, 348-355.	1.0	8
4	Preoperative systemic chemotherapy alters the histopathological growth patterns of colorectal liver metastases. Journal of Pathology: Clinical Research, 2022, 8, 48-64.	3.0	23
5	Preoperative predictors for early and very early disease recurrence in patients undergoing resection of pancreatic ductal adenocarcinoma. Hpb, 2022, 24, 535-546.	0.3	9
6	Systematic review and meta-analysis of validated prognostic models for resected hepatocellular carcinoma patients. European Journal of Surgical Oncology, 2022, 48, 492-499.	1.0	21
7	Impact of Complications After Pancreatoduodenectomy on Mortality, Organ Failure, Hospital Stay, and Readmission. Annals of Surgery, 2022, 275, e222-e228.	4.2	38
8	Detection, Treatment, and Survival of Pancreatic Cancer Recurrence in the Netherlands. Annals of Surgery, 2022, 275, 769-775.	4.2	32
9	Surgical Complications in a Multicenter Randomized Trial Comparing Preoperative Chemoradiotherapy and Immediate Surgery in Patients With Resectable and Borderline Resectable Pancreatic Cancer (PREOPANC Trial). Annals of Surgery, 2022, 275, 979-984.	4.2	26
10	Adjuvant intra-arterial chemotherapy for patients with resected colorectal liver metastases: a systematic review and meta-analysis. Hpb, 2022, 24, 299-308.	0.3	10
11	Sensitivity of CT, MRI, and EUS-FNA/B in the preoperative workup of histologically proven left-sided pancreatic lesions. Pancreatology, 2022, 22, 136-141.	1.1	3
12	Neoadjuvant therapy or upfront surgery for resectableÂand borderline resectable pancreatic cancer: AÂmeta-analysis of randomised controlled trials. European Journal of Cancer, 2022, 160, 140-149.	2.8	90
13	Development and external validation of a prediction model for overall survival after resection of distal cholangiocarcinoma. British Journal of Cancer, 2022, 126, 1280-1288.	6.4	4
14	FOLFIRINOX as Initial Treatment for Localized Pancreatic Adenocarcinoma: A Retrospective Analysis by the Trans-Atlantic Pancreatic Surgery Consortium. Journal of the National Cancer Institute, 2022, 114, 695-703.	6.3	20
15	Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial. Journal of Clinical Oncology, 2022, 40, 1220-1230.	1.6	274
16	Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry. Journal of Hepatology, 2022, 76, 1109-1121.	3.7	119
17	A Colon Resection and Pump Implantation in the Same Surgical Procedure: Is it Safe?. Annals of Surgical Oncology, 2022, 29, 2754.	1.5	0
18	Prognostic impact of perineural invasion in intrahepatic cholangiocarcinoma: multicentre study. British Journal of Surgery, 2022, 109, 610-616.	0.3	13

#	Article	IF	CITATIONS
19	High Systemic Immune Inflammation Index Is Associated With Low Skeletal Muscle Quantity in Resectable Pancreatic Ductal Adenocarcinoma. Frontiers in Oncology, 2022, 12, 827755.	2.8	5
20	ASO Visual Abstract: Hepatic ArterialÂInfusionÂPump Chemotherapy forÂUnresectableÂIntrahepaticÂCholangiocarcinoma—A Systematic ReviewÂand Meta-analysis. Annals of Surgical Oncology, 2022, , 1.	1.5	0
21	Tumor Necrosis Impacts Prognosis of Patients Undergoing Resection for T1 Intrahepatic Cholangiocarcinoma. Annals of Surgical Oncology, 2022, 29, 4326-4334.	1.5	7
22	ASO Visual Abstract: Tumor Necrosis Impacts the Prognosis of Patients Undergoing Resection for T1 Intrahepatic Cholangiocarcinoma. Annals of Surgical Oncology, 2022, , 1.	1.5	0
23	Sex, Gender and Age Differences in Treatment Allocation and Survival of Patients With Metastatic Pancreatic Cancer: A Nationwide Study. Frontiers in Oncology, 2022, 12, 839779.	2.8	9
24	Hepatic Arterial Infusion Pump Chemotherapy for Unresectable Intrahepatic Cholangiocarcinoma: A Systematic Review and Meta-Analysis. Annals of Surgical Oncology, 2022, 29, 5528-5538.	1.5	14
25	ASO Author Reflections: Usage of Hepatic Arterial Infusion Pump Chemotherapy for Unresectable Intrahepatic Cholangiocarcinoma. Annals of Surgical Oncology, 2022, , 1.	1.5	0
26	Realâ€world evidence of adjuvant gemcitabine plus capecitabine vs gemcitabine monotherapy for pancreatic ductal adenocarcinoma. International Journal of Cancer, 2022, 150, 1654-1663.	5.1	11
27	Age and prognosis in patients with pancreatic cancer: a population-based study. Acta Oncológica, 2022, 61, 286-293.	1.8	10
28	Predicting 10-year survival after resection of colorectal liver metastases; an international study including biomarkers and perioperative treatment. European Journal of Cancer, 2022, 168, 25-33.	2.8	25
29	Nationwide Validation of the 8th American Joint Committee on Cancer TNM Staging System and Five Proposed Modifications for Resected Pancreatic Cancer. Annals of Surgical Oncology, 2022, 29, 5988-5999.	1.5	11
30	Consensus Statement on Mandatory Measurements for Pancreatic Cancer Trials for Patients With Resectable or Borderline Resectable Disease (COMM-PACT-RB). JAMA Oncology, 2022, 8, 929.	7.1	4
31	ASO Visual Abstract: Nationwide Validation of the 8th American Joint Committee on Cancer TNM Staging System and Five Proposed Modifications for Resected Pancreatic Cancer. Annals of Surgical Oncology, 2022, , .	1.5	0
32	IMPACT OF ENDOSCOPIC ULTRASOUND EVALUATION WITH FINE-NEEDLE ASPIRATION OR FINE-NEEDLE BIOPSY IN RESECTABLE PERIHILAR CHOLANGIOCARCINOMA. Endoscopy, 2022, 54, .	1.8	0
33	A PROPENSITY MATCHED RETROSPECTIVE STUDY ON PREOPERATIVE BILIARY DRAINAGE IN PATIENTS WITH RESECTABLE PERIHILAR CHOLANGIOCARCINOMA: METAL BEATS PLASTIC STENTS?. Endoscopy, 2022, 54, .	1.8	0
34	INCIDENCE OF PANCREATIC CANCER WITHIN PANCREATIC CYSTIC NEOPLASM: 6-YEAR RESULTS FROM A NATIONWIDE PATHOLOGY DATABASE. Endoscopy, 2022, 54, .	1.8	0
35	PD-1+ T-Cells Correlate with Nerve Fiber Density as a Prognostic Biomarker in Patients with Resected Perihilar Cholangiocarcinoma. Cancers, 2022, 14, 2190.	3.7	4
36	Impact of Positive Lymph Nodes and Resection Margin Status on the Overall Survival of Patients with Resected Perihilar Cholangiocarcinoma: The ENSCCA Registry. Cancers, 2022, 14, 2389.	3.7	10

#	Article	IF	CITATIONS
37	Algorithm-based care versus usual care for the early recognition and management of complications after pancreatic resection in the Netherlands: an open-label, nationwide, stepped-wedge cluster-randomised trial. Lancet, The, 2022, 399, 1867-1875.	13.7	59
38	ASO Visual Abstract: Short- and Long-Term Outcomes of Pancreatic Cancer Resection for Elderly Patients: A Nationwide Analysis. Annals of Surgical Oncology, 2022, , 1.	1.5	0
39	Comparison of Hepatic Arterial Infusion Pump Chemotherapy vs Resection for Patients With Multifocal Intrahepatic Cholangiocarcinoma. JAMA Surgery, 2022, 157, 590.	4.3	25
40	Robotic distal pancreatectomy, a novel standard of care? First benchmark values for surgical outcomes from 14 international expert centers. British Journal of Surgery, 2022, 109, .	0.3	0
41	Short- and Long-Term Outcomes of Pancreatic Cancer Resection in Elderly Patients: A Nationwide Analysis. Annals of Surgical Oncology, 2022, 29, 6031-6042.	1.5	8
42	Timing of onset of systemic treatment in asymptomatic patients with metastatic pancreatic cancer: An international expert survey and case-vignette study Journal of Clinical Oncology, 2022, 40, e16256-e16256.	1.6	1
43	Treatment Response and Conditional Survival in Advanced Pancreatic Cancer Patients Treated with FOLFIRINOX: A Multicenter Cohort Study. Journal of Oncology, 2022, 2022, 1-9.	1.3	5
44	Neoadjuvant Radiotherapy After (m)FOLFIRINOX for Borderline Resectable Pancreatic Adenocarcinoma: A TAPS Consortium Study. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, 783-791.e1.	4.9	16
45	Significance of Examined Lymph Node Number in Accurate Staging and Long-term Survival in Resected Stage l–II Pancreatic Cancer—More is Better? A Large International Population-based Cohort Study. Annals of Surgery, 2021, 274, e554-e563.	4.2	31
46	International Validation of Reduced Major Morbidity After Minimally Invasive Distal Pancreatectomy Compared With Open Pancreatectomy. Annals of Surgery, 2021, 274, e966-e973.	4.2	20
47	Pancreatic resection in the pediatric, adolescent and young adult population: nationwide analysis on complications. Hpb, 2021, 23, 1175-1184.	0.3	3
48	Recurrence After Liver Resection of Colorectal Liver Metastases: Repeat Resection or Ablation Followed by Hepatic Arterial Infusion Pump Chemotherapy. Annals of Surgical Oncology, 2021, 28, 808-816.	1.5	11
49	Predicting Lymph Node Metastasis in Intrahepatic Cholangiocarcinoma. Journal of Gastrointestinal Surgery, 2021, 25, 1156-1163.	1.7	20
50	Extended Resections for Advanced Gallbladder Cancer: Results from a Nationwide Cohort Study. Annals of Surgical Oncology, 2021, 28, 835-843.	1.5	15
51	Nationwide practice and outcomes of endoscopic biliary drainage in resectable pancreatic head and periampullary cancer. Hpb, 2021, 23, 270-278.	0.3	10
52	Amsterdam International Consensus Meeting: tumor response scoring in the pathology assessment of resected pancreatic cancer after neoadjuvant therapy. Modern Pathology, 2021, 34, 4-12.	5.5	32
53	Impact of Primary Tumor Laterality on Adjuvant Hepatic Artery Infusion Pump Chemotherapy in Resected Colon Cancer Liver Metastases: Analysis of 487 Patients. Annals of Surgical Oncology, 2021, 28, 3685-3694.	1.5	3
54	Minimally invasive versus open distal pancreatectomy: an individual patient data meta-analysis of two randomized controlled trials. Hpb, 2021, 23, 323-330.	0.3	26

#	Article	lF	CITATIONS
55	Tumor Burden Dictates Prognosis Among Patients Undergoing Resection of Intrahepatic Cholangiocarcinoma: A Tool to Guide Post-Resection Adjuvant Chemotherapy?. Annals of Surgical Oncology, 2021, 28, 1970-1978.	1.5	30
56	Microscopic resection margin status in pancreatic ductal adenocarcinoma – A nationwide analysis. European Journal of Surgical Oncology, 2021, 47, 708-716.	1.0	5
57	Quality and performance of validated prognostic models for survival after resection of intrahepatic cholangiocarcinoma: a systematic review and meta-analysis. Hpb, 2021, 23, 25-36.	0.3	16
58	Transatlantic registries of pancreatic surgery in the United States of America, Germany, the Netherlands, and Sweden: Comparing design, variables, patients, treatment strategies, and outcomes. Surgery, 2021, 169, 396-402.	1.9	37
59	Eligibility for Liver Transplantation in Patients with Perihilar Cholangiocarcinoma. Annals of Surgical Oncology, 2021, 28, 1483-1492.	1.5	13
60	Robotic Total Pancreatectomy: A Narrative Review. In Vivo, 2021, 35, 1907-1911.	1.3	1
61	Venous wedge and segment resection during pancreatoduodenectomy for pancreatic cancer: impact on short- and long-term outcomes in a nationwide cohort analysis. British Journal of Surgery, 2021, 109, 96-104.	0.3	16
62	Axial slicing versus bivalving in the pathological examination of pancreatoduodenectomy specimens (APOLLO): a multicentre randomized controlled trial. Hpb, 2021, 23, 1349-1359.	0.3	6
63	Laparoscopic versus open extended radical left pancreatectomy for pancreatic ductal adenocarcinoma: an international propensity-score matched study. Surgical Endoscopy and Other Interventional Techniques, 2021, 35, 6949-6959.	2.4	3
64	Robotic <i>versus</i> laparoscopic distal pancreatectomy: multicentre analysis. British Journal of Surgery, 2021, 108, 188-195.	0.3	64
65	Surgical training model and safe implementation of robotic pancreatoduodenectomy in Japan: a technical note. World Journal of Surgical Oncology, 2021, 19, 55.	1.9	19
66	Robotic Total Pancreatectomy: A Novel Pancreatic Head-First Approach (with Video). Journal of Gastrointestinal Surgery, 2021, 25, 1649-1650.	1.7	4
67	The use and clinical outcome of total pancreatectomy in the United States, Germany, the Netherlands, and Sweden. Surgery, 2021, 170, 563-570.	1.9	15
68	Nationwide treatment and outcomes of perihilar cholangiocarcinoma. Liver International, 2021, 41, 1945-1953.	3.9	28
69	Histopathological Growth Patterns and Survival After Resection of Colorectal Liver Metastasis: An External Validation Study. JNCI Cancer Spectrum, 2021, 5, pkab026.	2.9	28
70	Proposed modification of the eighth edition of the AJCC staging system for intrahepatic cholangiocarcinoma. Hpb, 2021, 23, 1456-1466.	0.3	10
71	Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial. BMC Cancer, 2021, 21, 300.	2.6	95
72	Surgical morbidity in the first year after resection for perihilar cholangiocarcinoma. Hpb, 2021, 23, 1607-1614.	0.3	11

#	Article	IF	CITATIONS
73	Outcome after resection for perihilar cholangiocarcinoma in patients with primary sclerosing cholangitis: an international multicentre study. Hpb, 2021, 23, 1751-1758.	0.3	2
74	ASO Visual Abstract: Surgery for Bismuth–Corlette Type IV Perihilar Cholangiocarcinoma—Results from a Western Multicenter Collaborative Group. Annals of Surgical Oncology, 2021, 28, 460-461.	1.5	0
75	Randomized clinical trial and meta-analysis of the impact of a fibrin sealant patch on pancreatic fistula after distal pancreatectomy: CPR trial. BJS Open, 2021, 5, .	1.7	15
76	Preoperative chemoradiotherapy to improve overall survival in pancreatic cancer: Long-term results of the multicenter randomized phase III PREOPANC trial Journal of Clinical Oncology, 2021, 39, 4016-4016.	1.6	33
77	Surgery for Bismuth-Corlette Type 4 Perihilar Cholangiocarcinoma: Results from a Western Multicenter Collaborative Group. Annals of Surgical Oncology, 2021, 28, 7719-7729.	1.5	23
78	The value of serum amylase and drain fluid amylase to predict postoperative pancreatic fistula after pancreatoduodenectomy: a retrospective cohort study. Langenbeck's Archives of Surgery, 2021, 406, 2333-2341.	1.9	4
79	Total neoadjuvant FOLFIRINOX or gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2): A nationwide multicenter randomized controlled trial Journal of Clinical Oncology, 2021, 39, TPS4171-TPS4171.	1.6	3
80	Preoperative serum ADAM12 levels as a stromal marker for overall survival and benefit of adjuvant therapy in patients with resected pancreatic and periampullary cancer. Hpb, 2021, 23, 1886-1896.	0.3	3
81	The effect of preoperative chemotherapy and chemoradiotherapy on pancreatic fistula and other surgical complications after pancreatic resection: a systematic review and meta-analysis of comparative studies. Hpb, 2021, 23, 1321-1331.	0.3	16
82	ASO Visual Abstract: Added Value of Radiotherapy Following Neoadjuvant FOLFIRINOX for Resectable and Borderline Resectable Pancreatic Cancer—A Systematic Review and Meta-analysis. Annals of Surgical Oncology, 2021, 28, 485-487.	1.5	1
83	Added Value of Radiotherapy Following Neoadjuvant FOLFIRINOX for Resectable and Borderline Resectable Pancreatic Cancer: A Systematic Review and Meta-Analysis. Annals of Surgical Oncology, 2021, 28, 8297-8308.	1.5	19
84	Failure to Rescue After Pancreatoduodenectomy. Annals of Surgery, 2021, 274, 459-466.	4.2	26
85	Survival Benefit Associated With Resection of Locally Advanced Pancreatic Cancer After Upfront FOLFIRINOX Versus FOLFIRINOX Only. Annals of Surgery, 2021, 274, 729-735.	4.2	13
86	Perihilar Cholangiocarcinoma – Novel Benchmark Values for Surgical and Oncological Outcomes From 24 Expert Centers. Annals of Surgery, 2021, 274, 780-788.	4.2	72
87	A population-based study on incidence, treatment, and survival in ampullary cancer in the Netherlands. European Journal of Surgical Oncology, 2021, 47, 1742-1749.	1.0	5
88	The Impact of Neoadjuvant Treatment on Survival in Patients Undergoing Pancreatoduodenectomy With Concomitant Portomesenteric Venous Resection: An International Multicenter Analysis. Annals of Surgery, 2021, 274, 721-728.	4.2	24
89	Outcome of pancreatic anastomoses during pancreatoduodenectomy in two national audits. Surgery, 2021, 170, 1799-1806.	1.9	4
90	Stereotactic Body Radiation Therapy after Chemotherapy for Unresectable Perihilar Cholangiocarcinoma: The STRONG Trial, a Phase I Safety and Feasibility Study. Cancers, 2021, 13, 3991.	3.7	6

#	Article	IF	CITATIONS
91	Minimally invasive versus open distal pancreatectomy for pancreatic ductal adenocarcinoma (DIPLOMA): study protocol for a randomized controlled trial. Trials, 2021, 22, 608.	1.6	22
92	Long-Term Quality of Life after Minimally Invasive vs Open Distal Pancreatectomy in the LEOPARD Randomized Trial. Journal of the American College of Surgeons, 2021, 233, 730-739e9.	0.5	19
93	Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma. Hepatology, 2021, 74, 1429-1444.	7.3	73
94	771 IMPACT OF NATIONWIDE CENTRALIZATION OF ESOPHAGEAL, GASTRIC, AND PANCREATIC SURGERY ON TRAVEL DISTANCE AND EXPERIENCED BURDEN IN THE NETHERLANDS. Ecological Management and Restoration, 2021, 34, .	0.4	0
95	Locoregional therapies in patients with intrahepatic cholangiocarcinoma: A systematic review and pooled analysis. Cancer Treatment Reviews, 2021, 99, 102258.	7.7	45
96	Distinguishing pure histopathological growth patterns of colorectal liver metastases on CT using deep learning and radiomics: a pilot study. Clinical and Experimental Metastasis, 2021, 38, 483-494.	3.3	24
97	Organoids Derived from Neoadjuvant FOLFIRINOX Patients Recapitulate Therapy Resistance in Pancreatic Ductal Adenocarcinoma. Clinical Cancer Research, 2021, 27, 6602-6612.	7.0	22
98	1473P Gender differences in treatment allocation and survival in a real-world metastatic pancreatic cancer cohort. Annals of Oncology, 2021, 32, S1089.	1.2	0
99	Preoperative misdiagnosis of pancreatic and periampullary cancer in patients undergoing pancreatoduodenectomy: A multicentre retrospective cohort study. European Journal of Surgical Oncology, 2021, 47, 2525-2532.	1.0	21
100	Primary and secondary liver failure after major liver resection for perihilar cholangiocarcinoma. Surgery, 2021, 170, 1024-1030.	1.9	18
101	Circulating <i>TP53</i> mutations are associated with early tumor progression and poor survival in pancreatic cancer patients treated with FOLFIRINOX. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110337.	3.2	8
102	Completion pancreatectomy or a pancreas-preserving procedure during relaparotomy for pancreatic fistula after pancreatoduodenectomy: a multicentre cohort study and meta-analysis. British Journal of Surgery, 2021, 108, 1371-1379.	0.3	16
103	Number and Station of Lymph Node Metastasis After Curative-intent Resection of Intrahepatic Cholangiocarcinoma Impact Prognosis. Annals of Surgery, 2021, 274, e1187-e1195.	4.2	105
104	Primary Sclerosing Cholangitis–Associated Cholangiocarcinoma Demonstrates High Intertumor and Intratumor Heterogeneity. Clinical and Translational Gastroenterology, 2021, 12, e00410.	2.5	5
105	Endoscopic ultrasonography as additional preoperative workup is valuable in half of the patients with a pancreatic body or tail lesion. Hpb, 2021, , .	0.3	0
106	Serum miR-373-3p and miR-194-5p Are Associated with Early Tumor Progression during FOLFIRINOX Treatment in Pancreatic Cancer Patients: A Prospective Multicenter Study. International Journal of Molecular Sciences, 2021, 22, 10902.	4.1	9
107	Resection of the Portal-Superior Mesenteric Vein in Pancreatic Cancer. Pancreas, 2021, 50, 1218-1229.	1.1	4
108	Early Detection and Minimally Invasive Management of Complications Reduces Mortality after Pancreatic Resection: The Nationwide PORSCH Trial. Hpb, 2021, 23, S672.	0.3	1

#	Article	IF	CITATIONS
109	Micronutrient deficiencies and anaemia in patients after pancreatoduodenectomy. British Journal of Surgery, 2021, 108, e74-e75.	0.3	3
110	Primary and secondary liver failure after major liver resection for perihilar cholangiocarcinoma. Hpb, 2021, 23, S821-S822.	0.3	0
111	Actual 10-Year Survival after Resection of Perihilar Cholangiocarcinoma: What Factors Preclude a Chance for Cure?. Cancers, 2021, 13, 6260.	3.7	9
112	Toward an Optimized Staging System for Pancreatic Ductal Adenocarcinoma: A Clinically Interpretable, Artificial Intelligence–Based Model. JCO Clinical Cancer Informatics, 2021, 5, 1220-1231.	2.1	5
113	Evaluation of the New American Joint Committee on Cancer Staging Manual 8th Edition for Perihilar Cholangiocarcinoma. Journal of Gastrointestinal Surgery, 2020, 24, 1612-1618.	1.7	24
114	The systemic immuneâ€inflammation index is associated with an increased risk of incident cancer—A populationâ€based cohort study. International Journal of Cancer, 2020, 146, 692-698.	5.1	95
115	Outcomes After Minimally-invasive Versus Open Pancreatoduodenectomy. Annals of Surgery, 2020, 271, 356-363.	4.2	113
116	Screening for colorectal cancer after pancreatoduodenectomy for ampullary cancer. European Journal of Surgical Oncology, 2020, 46, 534-538.	1.0	0
117	Recurrence Patterns After Resection of Colorectal Liver Metastasis are Modified by Perioperative Systemic Chemotherapy. World Journal of Surgery, 2020, 44, 876-886.	1.6	17
118	A Machine-Based Approach to Preoperatively Identify Patients with the Most and Least Benefit Associated withÂResection for Intrahepatic Cholangiocarcinoma: An International Multi-institutional Analysis of 1146 Patients. Annals of Surgical Oncology, 2020, 27, 1110-1119.	1.5	41
119	International validation and update of the Amsterdam model for prediction of survival after pancreatoduodenectomy for pancreatic cancer. European Journal of Surgical Oncology, 2020, 46, 796-803.	1.0	14
120	The impact of hepatic arterial infusion pump chemotherapy on hepatic recurrences and survival in patients with resected colorectal liver metastases. Hpb, 2020, 22, 1271-1279.	0.3	8
121	Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium. Gut, 2020, 69, 7-17.	12.1	357
122	The risk of not receiving adjuvant chemotherapy after resection of pancreatic ductal adenocarcinoma: a nationwide analysis. Hpb, 2020, 22, 233-240.	0.3	66
123	Primary tumor location and the prognosis of patients after local treatment of colorectal liver metastases: a systematic review and meta-analysis. Hpb, 2020, 22, 351-357.	0.3	17
124	Histopathological growth patterns and positive margins after resection of colorectal liver metastases. Hpb, 2020, 22, 911-919.	0.3	23
125	Redefining Conditional Overall and Disease-Free Survival After Curative Resection for Intrahepatic Cholangiocarcinoma: a Multi-institutional, International Study of 1221 patients. Journal of Gastrointestinal Surgery, 2020, 24, 2756-2765.	1.7	5
126	Nationwide trends in incidence, treatmentÂand survival of pancreatic ductal adenocarcinoma. European Journal of Cancer, 2020, 125, 83-93.	2.8	98

#	Article	IF	CITATIONS
127	Textbook Outcome. Annals of Surgery, 2020, 271, 155-162.	4.2	137
128	Defining Benchmark Outcomes for Pancreatoduodenectomy With Portomesenteric Venous Resection. Annals of Surgery, 2020, 272, 731-737.	4.2	49
129	C-reactive protein is superior to white blood cell count for early detection of complications after pancreatoduodenectomy: a retrospective multicenter cohort study. Hpb, 2020, 22, 1504-1512.	0.3	12
130	Histopathological growth patterns as biomarker for adjuvant systemic chemotherapy in patients with resected colorectal liver metastases. Clinical and Experimental Metastasis, 2020, 37, 593-605.	3.3	27
131	Severe Salmonella spp. or Campylobacter spp. Infection and the Risk of Biliary Tract Cancer: A Population-Based Study. Cancers, 2020, 12, 3348.	3.7	3
132	Very Early Recurrence After Liver Resection for Intrahepatic Cholangiocarcinoma. JAMA Surgery, 2020, 155, 823.	4.3	116
133	Prophylactic total pancreatectomy in individuals at high risk of pancreatic ductal adenocarcinoma (PROPAN): systematic review and shared decisionâ€making programme using decision tables. United European Gastroenterology Journal, 2020, 8, 865-877.	3.8	11
134	Nationwide compliance with a multidisciplinary guideline on pancreatic cancer during 6-year follow-up. Pancreatology, 2020, 20, 1723-1731.	1.1	9
135	Impact of time interval between multidisciplinary team meeting and intended pancreatoduodenectomy on oncological outcomes. BJS Open, 2020, 4, 884-892.	1.7	5
136	Evaluation of Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer After Neoadjuvant FOLFIRINOX Treatment. JAMA Oncology, 2020, 6, 1733.	7.1	85
137	Care after pancreatic resection according to an algorithm for early detection and minimally invasive management of pancreatic fistula versus current practice (PORSCH-trial): design and rationale of a nationwide stepped-wedge cluster-randomized trial. Trials, 2020, 21, 389.	1.6	21
138	The yield of chest computed tomography in patients with locally advanced pancreatic cancer. Journal of Surgical Oncology, 2020, 122, 450-456.	1.7	3
139	Treatment and Survival of Elderly Patients with Stage l–Il Pancreatic Cancer: A Report of the EURECCA Pancreas Consortium. Annals of Surgical Oncology, 2020, 27, 5337-5346.	1.5	9
140	Assessing Textbook Outcomes Following Liver Surgery for Primary Liver Cancer Over a 12-Year Time Period at Major Hepatobiliary Centers. Annals of Surgical Oncology, 2020, 27, 3318-3327.	1.5	59
141	Advances in adjuvant therapy of biliary tract cancer: an overview of current clinical evidence based on phase II and III trials. Critical Reviews in Oncology/Hematology, 2020, 151, 102975.	4.4	14
142	A Novel Classification of Intrahepatic Cholangiocarcinoma Phenotypes Using Machine Learning Techniques: An International Multi-Institutional Analysis. Annals of Surgical Oncology, 2020, 27, 5224-5232.	1.5	20
143	Establishing and Coordinating a Nationwide Multidisciplinary Study Group: Lessons Learned by the Dutch Pancreatic Cancer Group. Annals of Surgery, 2020, 271, e102-e104.	4.2	43
144	Robotic Pancreatoduodenectomy: Patient Selection, Volume Criteria, and Training Programs. Scandinavian Journal of Surgery, 2020, 109, 29-33.	2.6	18

#	Article	IF	CITATIONS
145	Patient-reported burden of intensified surveillance and surgery in high-risk individuals under pancreatic cancer surveillance. Familial Cancer, 2020, 19, 247-258.	1.9	7
146	The Impact of Preoperative CA19-9 and CEA on Outcomes of Patients with Intrahepatic Cholangiocarcinoma. Annals of Surgical Oncology, 2020, 27, 2888-2901.	1.5	44
147	Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nature Reviews Gastroenterology and Hepatology, 2020, 17, 557-588.	17.8	1,155
148	Development and Validation of a Laboratory Risk Score (LabScore) to Predict Outcomes after Resection for Intrahepatic Cholangiocarcinoma. Journal of the American College of Surgeons, 2020, 230, 381-391e2.	0.5	31
149	Yttrium-90 Radioembolization in Intrahepatic Cholangiocarcinoma: A Multicenter Retrospective Analysis. Journal of Vascular and Interventional Radiology, 2020, 31, 1035-1043.e2.	0.5	49
150	Neoadjuvant Treatment in Patients With Resectable and Borderline Resectable Pancreatic Cancer. Frontiers in Oncology, 2020, 10, 41.	2.8	68
151	Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial. Journal of Clinical Oncology, 2020, 38, 1763-1773.	1.6	665
152	Portal Vein Embolization is Associated with Reduced Liver Failure and Mortality in High-Risk Resections for Perihilar Cholangiocarcinoma. Annals of Surgical Oncology, 2020, 27, 2311-2318.	1.5	46
153	Conditional Survival After Resection for Pancreatic Cancer: A Population-Based Study and Prediction Model. Annals of Surgical Oncology, 2020, 27, 2516-2524.	1.5	36
154	Disease-free interval and tumor functional status can be used to select patients for resection/ablation of liver metastases from adrenocortical carcinoma: insights from a multi-institutional study. Hpb, 2020, 22, 169-175.	0.3	9
155	The systemic immune-inflammation index predicts prognosis in intrahepatic cholangiocarcinoma: an international multi-institutional analysis. Hpb, 2020, 22, 1667-1674.	0.3	37
156	Trends in Treatment and Survival of Gallbladder Cancer in the Netherlands; Identifying Gaps and Opportunities from a Nation-Wide Cohort. Cancers, 2020, 12, 918.	3.7	18
157	Should jaundice preclude resection in patients with gallbladder cancer? Results from a nation-wide cohort study. Hpb, 2020, 22, 1686-1694.	0.3	7
158	C-reactive protein is superior to white blood cell count for early prediction of major complications after pancreatoduodenectomy. Hpb, 2020, 22, S422.	0.3	1
159	Relationship Between Quality of Life and Survival in Patients With Pancreatic and Periampullary Cancer: A Multicenter Cohort Analysis. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 1354-1363.	4.9	11
160	Added Value of Body Fat Distribution in Predicting Clinically Significant Pancreatic Fistula in the a-FRS Following Pancreatoduodenectomy Currently Unclear. Annals of Surgery, 2019, 269, e2-e3.	4.2	7
161	A comparison of treatment and outcomes of perihilar cholangiocarcinoma between Eastern and Western centers. Hpb, 2019, 21, 345-351.	0.3	46
162	Discordance in prediction of prognosis among patients with intrahepatic cholangiocarcinoma: A preoperative vs postoperative perspective. Journal of Surgical Oncology, 2019, 120, 946-955.	1.7	6

#	Article	IF	CITATIONS
163	Intrahepatic cholangiocarcinoma tumor burden: A classification and regression tree model to define prognostic groups after resection. Surgery, 2019, 166, 983-990.	1.9	54
164	Locally Advanced Pancreatic Cancer: Work-Up, Staging, and Local Intervention Strategies. Cancers, 2019, 11, 976.	3.7	63
165	Yield of staging laparoscopy before treatment of locally advanced pancreatic cancer to detect occult metastases. European Journal of Surgical Oncology, 2019, 45, 1906-1911.	1.0	22
166	Patient-reported burden of intensified surveillance and surgery in high-risk individuals under pancreatic cancer surveillance. Pancreatology, 2019, 19, S31.	1.1	0
167	Adjuvant Hepatic Arterial Infusion Pump Chemotherapy After Resection of Colorectal Liver Metastases: Results of a Safety and Feasibility Study in The Netherlands. Annals of Surgical Oncology, 2019, 26, 4599-4607.	1.5	19
168	Recreating Tumour Complexity in a Dish: Organoid Models to Study Liver Cancer Cells and their Extracellular Environment. Cancers, 2019, 11, 1706.	3.7	26
169	Current evidence of nutritional therapy in pancreatoduodenectomy: Systematic review of randomized controlled trials. Annals of Gastroenterological Surgery, 2019, 3, 620-629.	2.4	14
170	Radial margin status should be determined in resected perihilar cholangiocarcinoma. Hepatobiliary Surgery and Nutrition, 2019, 8, 557-559.	1.5	3
171	PO-0791 Neoadjuvant treatment potentially improves outcome in resectable pancreatic cancer: metaanalysis. Radiotherapy and Oncology, 2019, 133, S408-S409.	0.6	0
172	Body Composition Is an Independent Predictor of Outcome in Patients with Hepatocellular Carcinoma Treated with Sorafenib. Liver Cancer, 2019, 8, 255-270.	7.7	30
173	Laparoscopic versus open pancreatoduodenectomy for pancreatic or periampullary tumours (LEOPARD-2): a multicentre, patient-blinded, randomised controlled phase 2/3 trial. The Lancet Gastroenterology and Hepatology, 2019, 4, 199-207.	8.1	393
174	Variation in pancreatoduodenectomy as delivered in two national audits. British Journal of Surgery, 2019, 106, 747-755.	0.3	24
175	Circulating Biomarkers for Prediction of Objective Response to Chemotherapy in Pancreatic Cancer Patients. Cancers, 2019, 11, 93.	3.7	22
176	Postoperative surveillance of pancreatic cancer patients. European Journal of Surgical Oncology, 2019, 45, 1770-1777.	1.0	32
177	Reduction of immunosuppressive tumor microenvironment in cholangiocarcinoma by ex vivo targeting immune checkpoint molecules. Journal of Hepatology, 2019, 71, 753-762.	3.7	81
178	Therapeutic Index Associated with Lymphadenectomy Among Patients with Intrahepatic Cholangiocarcinoma: Which Patients Benefit the Most from Nodal Evaluation?. Annals of Surgical Oncology, 2019, 26, 2959-2968.	1.5	43
179	Histopathological growth patterns as a guide for adjuvant systemic chemotherapy in patients with resected colorectal liver metastases. European Journal of Surgical Oncology, 2019, 45, e10.	1.0	2
180	Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis. Journal of the National Cancer Institute, 2019, 111, 782-794.	6.3	223

#	Article	IF	CITATIONS
181	A Multi-institutional International Analysis of Textbook Outcomes Among Patients Undergoing Curative-Intent Resection of Intrahepatic Cholangiocarcinoma. JAMA Surgery, 2019, 154, e190571.	4.3	149
182	Costs and quality of life in a randomized trial comparing minimally invasive and open distal pancreatectomy (LEOPARD trial). British Journal of Surgery, 2019, 106, 910-921.	0.3	41
183	Prognostic utility of albuminâ€bilirubin grade for short―and longâ€ŧerm outcomes following hepatic resection for intrahepatic cholangiocarcinoma: A multiâ€institutional analysis of 706 patients. Journal of Surgical Oncology, 2019, 120, 206-213.	1.7	39
184	A novel online prognostic tool to predict longâ€ŧerm survival after liver resection for intrahepatic cholangiocarcinoma: The "metroâ€ŧicket―paradigm. Journal of Surgical Oncology, 2019, 120, 223-230.	1.7	26
185	Recurrence Patterns and Timing Courses Following Curative-Intent Resection for Intrahepatic Cholangiocarcinoma. Annals of Surgical Oncology, 2019, 26, 2549-2557.	1.5	74
186	Survival after Resection of Multiple Tumor Foci of Intrahepatic Cholangiocarcinoma. Journal of Gastrointestinal Surgery, 2019, 23, 2239-2246.	1.7	32
187	Surgery for cholangiocarcinoma. Liver International, 2019, 39, 143-155.	3.9	192
188	Treatment and survival of resected and unresected distal cholangiocarcinoma: a nationwide study. Acta Oncológica, 2019, 58, 1048-1055.	1.8	74
189	Impact of body mass index on tumor recurrence among patients undergoing curative-intent resection of intrahepatic cholangiocarcinoma- a multi-institutional international analysis. European Journal of Surgical Oncology, 2019, 45, 1084-1091.	1.0	13
190	Should Utilization of Lymphadenectomy Vary According to Morphologic Subtype of Intrahepatic Cholangiocarcinoma?. Annals of Surgical Oncology, 2019, 26, 2242-2250.	1.5	27
191	Adjuvant hepatic arterial infusion pump chemotherapy and resection versus resection alone in patients with low-risk resectable colorectal liver metastases – the multicenter randomized controlled PUMP trial. BMC Cancer, 2019, 19, 327.	2.6	33
192	Systematic review of clinical prediction models for survival after surgery for resectable pancreatic cancer. British Journal of Surgery, 2019, 106, 342-354.	0.3	38
193	Efficacy and feasibility of stereotactic radiotherapy after folfirinox in patients with locally advanced pancreatic cancer (LAPC-1 trial). EClinicalMedicine, 2019, 17, 100200.	7.1	41
194	Benchmarks in Pancreatic Surgery. Annals of Surgery, 2019, 270, 211-218.	4.2	202
195	Response to the Comment on "Prediction of Hepatocellular Carcinoma Recurrence Beyond Milan Criteria After Resection: Validation of a Clinical Risk Score in Aninternational Cohort― Annals of Surgery, 2019, 269, e34-e35.	4.2	0
196	Oncologic outcomes of minimally invasive versus open distal pancreatectomy for pancreatic ductal adenocarcinoma: A systematic review and meta-analysis. European Journal of Surgical Oncology, 2019, 45, 719-727.	1.0	67
197	The neutrophil-to-lymphocyte ratio is associated with mortality in the general population: The Rotterdam Study. European Journal of Epidemiology, 2019, 34, 463-470.	5.7	81
198	Minimally Invasive Versus Open Distal Pancreatectomy (LEOPARD). Annals of Surgery, 2019, 269, 2-9.	4.2	401

#	Article	IF	CITATIONS
199	Impact of microvascular invasion on clinical outcomes after curativeâ€intent resection for intrahepatic cholangiocarcinoma. Journal of Surgical Oncology, 2019, 119, 21-29.	1.7	33
200	Alternative Fistula Risk Score for Pancreatoduodenectomy (a-FRS). Annals of Surgery, 2019, 269, 937-943.	4.2	257
201	Minimally Invasive versus Open Distal Pancreatectomy for Ductal Adenocarcinoma (DIPLOMA). Annals of Surgery, 2019, 269, 10-17.	4.2	211
202	The Systemic-immune-inflammation Index Independently Predicts Survival and Recurrence in Resectable Pancreatic Cancer and its Prognostic Value Depends on Bilirubin Levels. Annals of Surgery, 2019, 270, 139-146.	4.2	179
203	Low Skeletal Muscle Density Is Associated with Early Death in Patients with Perihilar Cholangiocarcinoma Regardless of Subsequent Treatment. Digestive Surgery, 2019, 36, 144-152.	1.2	31
204	Unsupervised Subtyping of Cholangiocarcinoma Using a Deep Clustering Convolutional Autoencoder. Lecture Notes in Computer Science, 2019, , 604-612.	1.3	14
205	Significance of examined lymph node number in accurate staging and long-term survival in resected stage I-II pancreatic cancer: More is better? A large international population-based cohort study Journal of Clinical Oncology, 2019, 37, 6503-6503.	1.6	1
206	The Dutch Pancreas Biobank Within the Parelsnoer Institute. Pancreas, 2018, 47, 495-501.	1.1	8
207	Trends in use of lymphadenectomy in surgery with curative intent for intrahepatic cholangiocarcinoma. British Journal of Surgery, 2018, 105, 857-866.	0.3	74
208	Preoperative Risk Score to Predict Occult Metastatic or Locally Advanced Disease in Patients with Resectable Perihilar Cholangiocarcinoma on Imaging. Journal of the American College of Surgeons, 2018, 227, 238-246e2.	0.5	11
209	Quantitative Imaging Features and Postoperative Hepatic Insufficiency: A Multi-Institutional Expanded Cohort. Journal of the American College of Surgeons, 2018, 226, 835-843.	0.5	7
210	Perioperative and long-term outcome of intrahepatic cholangiocarcinoma involving the hepatic hilus after curative-intent resection: comparison with peripheral intrahepatic cholangiocarcinoma and hilar cholangiocarcinoma. Surgery, 2018, 163, 1114-1120.	1.9	27
211	Actual 10-year survival after hepatic resection of colorectal liver metastases: what factors preclude cure?. Surgery, 2018, 163, 1238-1244.	1.9	147
212	The Limitations of Standard Clinicopathologic Features to Accurately Risk-Stratify Prognosis after Resection of Intrahepatic Cholangiocarcinoma. Journal of Gastrointestinal Surgery, 2018, 22, 477-485.	1.7	16
213	Preoperative Risk Score and Prediction of Long-Term Outcomes after Hepatectomy for Intrahepatic Cholangiocarcinoma. Journal of the American College of Surgeons, 2018, 226, 393-403.	0.5	37
214	Translating the ABC-02 trial into daily practice: outcome of palliative treatment in patients with unresectable biliary tract cancer treated with gemcitabine and cisplatin. Acta Oncológica, 2018, 57, 807-812.	1.8	24
215	Surgical Management of Intrahepatic Cholangiocarcinoma in Patients with Cirrhosis: Impact of Lymphadenectomy on Periâ€Operative Outcomes. World Journal of Surgery, 2018, 42, 2551-2560.	1.6	47
216	Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer. British Journal of Surgery, 2018, 105, 946-958.	0.3	384

#	Article	IF	CITATIONS
217	Variation in hospital mortality after pancreatoduodenectomy is related to failure to rescue rather than major complications: a nationwide audit. Hpb, 2018, 20, 759-767.	0.3	85
218	Assessment of the Lymph Node Status in Patients Undergoing Liver Resection for Intrahepatic Cholangiocarcinoma: the New Eighth Edition AJCC Staging System. Journal of Gastrointestinal Surgery, 2018, 22, 52-59.	1.7	92
219	The prognostic value of portal vein and hepatic artery involvement in patients with perihilar cholangiocarcinoma. Hpb, 2018, 20, 83-92.	0.3	45
220	Implications of Intrahepatic Cholangiocarcinoma Etiology on Recurrence and Prognosis after Curativeâ€Intent Resection: a Multiâ€Institutional Study. World Journal of Surgery, 2018, 42, 849-857.	1.6	17
221	The Impact of Primary Tumor Location on Long-Term Survival in Patients Undergoing Hepatic Resection for Metastatic Colon Cancer. Annals of Surgical Oncology, 2018, 25, 431-438.	1.5	76
222	Early <i>versus</i> late recurrence of intrahepatic cholangiocarcinoma after resection with curative intent. British Journal of Surgery, 2018, 105, 848-856.	0.3	158
223	A preliminary prediction model for potentially guiding patient choices between breast conserving surgery and mastectomy in early breast cancer patients; a Dutch experience. Quality of Life Research, 2018, 27, 545-553.	3.1	8
224	FOLFIRINOX and radiotherapy for locally advanced pancreatic cancer: A cohort study. Journal of Surgical Oncology, 2018, 118, 1021-1026.	1.7	20
225	Association of the location of pancreatic ductal adenocarcinoma (head, body, tail) with tumor stage, treatment, and survival: a population-based analysis. Acta Oncológica, 2018, 57, 1655-1662.	1.8	70
226	International Validation of the Eighth Edition of the American Joint Committee on Cancer (AJCC) TNM Staging System in Patients With Resected Pancreatic Cancer. JAMA Surgery, 2018, 153, e183617.	4.3	213
227	Protocol for the STRONG trial: stereotactic body radiation therapy following chemotherapy for unresectable perihilar cholangiocarcinoma, a phase I feasibility study. BMJ Open, 2018, 8, e020731.	1.9	10
228	Trends in treatment and survival of patients with nonresected, nonmetastatic pancreatic cancer: A populationâ€based study. Cancer Medicine, 2018, 7, 4943-4951.	2.8	23
229	New-onset diabetes after pancreatoduodenectomy: A systematic review and meta-analysis. Surgery, 2018, 164, 6-16.	1.9	27
230	Sarcopenia is not a predictor of survival or sorafenib toxicity in advanced hepatocellular carcinoma: A Dutch multicenter study. Journal of Hepatology, 2018, 68, S434.	3.7	0
231	Clinical impact of the updated international postoperative pancreatic fistula definition in distal pancreatectomy. Hpb, 2018, 20, 1044-1050.	0.3	18
232	Long-term outcomes of patients with intraductal growth sub-type of intrahepatic cholangiocarcinoma. Hpb, 2018, 20, 1189-1197.	0.3	18
233	Surgery for perihilar cholangiocarcinoma. British Journal of Surgery, 2018, 105, 771-772.	0.3	3
234	Minimally invasive versus open pancreatoduodenectomy (LEOPARD-2): study protocol for a randomized controlled trial. Trials, 2018, 19, 1.	1.6	107

#	Article	lF	CITATIONS
235	Endoscopic versus percutaneous biliary drainage in patients with resectable perihilar cholangiocarcinoma: a multicentre, randomised controlled trial. The Lancet Gastroenterology and Hepatology, 2018, 3, 681-690.	8.1	126
236	A preoperative prognostic model to predict surgical success in patients with perihilar cholangiocarcinoma. Journal of Surgical Oncology, 2018, 118, 469-476.	1.7	15
237	Serum tumor markers enhance the predictive power of the AJCC and LCSGJ staging systems in resectable intrahepatic cholangiocarcinoma. Hpb, 2018, 20, 956-965.	0.3	28
238	Characteristics of postoperative pancreatic fistula on CT scan: A multicenter cohort study. Pancreatology, 2018, 18, S5-S6.	1.1	0
239	The impact of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio among patients with intrahepatic cholangiocarcinoma. Surgery, 2018, 164, 411-418.	1.9	38
240	Preoperative prognostic nutritional index predicts survival of patients with intrahepatic cholangiocarcinoma after curative resection. Journal of Surgical Oncology, 2018, 118, 422-430.	1.7	33
241	Neoadjuvant FOLFIRINOX in patients with (borderline) resectable pancreatic cancer: A systematic review and patient-level meta-analysis Journal of Clinical Oncology, 2018, 36, e16207-e16207.	1.6	2
242	The effect of preoperative chemotherapy treatment in surgically treated intrahepatic cholangiocarcinoma patients—A multiâ€institutional analysis. Journal of Surgical Oncology, 2017, 115, 312-318.	1.7	46
243	Comparative performances of the 7th and the 8th editions of the American Joint Committee on Cancer staging systems for intrahepatic cholangiocarcinoma. Journal of Surgical Oncology, 2017, 115, 696-703.	1.7	85
244	Minimally invasive versus open distal pancreatectomy (LEOPARD): study protocol for a randomized controlled trial. Trials, 2017, 18, 166.	1.6	40
245	Impact of major vascular resection on outcomes and survival in patients with intrahepatic cholangiocarcinoma: A multiâ€institutional analysis. Journal of Surgical Oncology, 2017, 116, 133-139.	1.7	57
246	Impact of Morphological Status on Long-Term Outcome Among Patients Undergoing Liver Surgery for Intrahepatic Cholangiocarcinoma. Annals of Surgical Oncology, 2017, 24, 2491-2501.	1.5	31
247	Validation of the Mayo Clinic Staging System in Determining Prognoses of Patients With Perihilar Cholangiocarcinoma. Clinical Gastroenterology and Hepatology, 2017, 15, 1930-1939.e3.	4.4	15
248	High mortality after ALPPS for perihilar cholangiocarcinoma: case-control analysis including the first series from the international ALPPS registry. Hpb, 2017, 19, 381-387.	0.3	111
249	Defining Long-Term Survivors Following Resection of Intrahepatic Cholangiocarcinoma. Journal of Gastrointestinal Surgery, 2017, 21, 1888-1897.	1.7	31
250	Surgical Site Infection Is Associated with Tumor Recurrence in Patients with Extrahepatic Biliary Malignancies. Journal of Gastrointestinal Surgery, 2017, 21, 1813-1820.	1.7	12
251	Performance of prognostic scores and staging systems in predicting longâ€ŧerm survival outcomes after surgery for intrahepatic cholangiocarcinoma. Journal of Surgical Oncology, 2017, 116, 1085-1095.	1.7	42
252	Sarcopenia is associated with increased hospital expenditure in patients undergoing major cancer surgery of the alimentary tract. Journal of Hepatology, 2017, 66, S185.	3.7	0

#	Article	IF	CITATIONS
253	The prognostic value of hepatic artery and portal vein involvement in patients with perihilar cholangiocarcinoma. Journal of Hepatology, 2017, 66, S447.	3.7	0
254	Impact of adjuvant chemotherapy on survival in patients with intrahepatic cholangiocarcinoma: a multi-institutional analysis. Hpb, 2017, 19, 901-909.	0.3	74
255	Conditional probability of long-term survival in patients with locally advanced and metastatic hilar cholangiocarcinoma. Journal of Hepatology, 2017, 66, S446-S447.	3.7	0
256	Survival after resection of perihilar cholangiocarcinoma inÂpatients with lymph node metastases. Hpb, 2017, 19, 735-740.	0.3	27
257	Lymph Node Staging in Patients Undergoing Hepatectomy for Intrahepatic Cholangiocarcinoma: An International Multicentric Analysis. Gastroenterology, 2017, 152, S1223.	1.3	0
258	Perioperative and Long-Term Outcome for Intrahepatic Cholangiocarcinoma: Impact of Major Versus Minor Hepatectomy. Journal of Gastrointestinal Surgery, 2017, 21, 1841-1850.	1.7	65
259	A National Survey on Peri-interventional Management of Percutaneous Transhepatic Biliary Drainage. Surgical Laparoscopy, Endoscopy and Percutaneous Techniques, 2017, 27, 253-256.	0.8	3
260	Sarcopenia is associated with hospital expenditure in patients undergoing cancer surgery of the alimentary tract. Hpb, 2017, 19, S46-S47.	0.3	0
261	The prognostic value of hepatic arterial and portal venous involvement in patients with perihilar cholangiocarcinoma. Hpb, 2017, 19, S47.	0.3	1
262	Low skeletal muscle density is associated with early death in patients with suspected perihilar cholangiocarcinoma. Hpb, 2017, 19, S34-S35.	0.3	0
263	Nationwide prospective audit of pancreatic surgery: design, accuracy, and outcomes of the Dutch Pancreatic Cancer Audit. Hpb, 2017, 19, 919-926.	0.3	97
264	Conditional survival in patients with unresectable perihilar cholangiocarcinoma. Hpb, 2017, 19, 966-971.	0.3	15
265	Quantitative Imaging Features of Preoperative Computed Tomography Images Predict Post-Hepatectomy Liver Insufficiency: A Multi-Institutional Expansion Cohort. Journal of the American College of Surgeons, 2017, 225, S137.	0.5	0
266	Postoperative Liver Failure Risk Score: Identifying Patients with Resectable Perihilar Cholangiocarcinoma Who Can Benefit from Portal Vein Embolization. Journal of the American College of Surgeons, 2017, 225, 387-394.	0.5	87
267	Prediction of Hepatocellular Carcinoma Recurrence Beyond Milan Criteria After Resection. Annals of Surgery, 2017, 266, 693-701.	4.2	86
268	Intrahepatic cholangiocarcinoma: current perspectives. OncoTargets and Therapy, 2017, Volume 10, 1131-1142.	2.0	115
269	Perioperative Hepatic Arterial Infusion Pump Chemotherapy Is Associated With Longer Survival After Resection of Colorectal Liver Metastases: A Propensity Score Analysis. Journal of Clinical Oncology, 2017, 35, 1938-1944.	1.6	112
270	Reply to H. Zhang et al. Journal of Clinical Oncology, 2017, 35, 3266-3267.	1.6	0

#	Article	IF	CITATIONS
271	Developing a robotic pancreas program: the Dutch experience. Journal of Visualized Surgery, 2017, 3, 106-106.	0.2	31
272	Right versus left: Impact of primary location on survival and cure in patients undergoing hepatic resection for metastatic colon cancer Journal of Clinical Oncology, 2017, 35, 664-664.	1.6	3
273	Low skeletal muscle mass is associated with increased hospital expenditure in patients undergoing cancer surgery of the alimentary tract. PLoS ONE, 2017, 12, e0186547.	2.5	38
274	Unresectable intrahepatic cholangiocarcinoma: Systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone. Cancer, 2016, 122, 758-765.	4.1	138
275	Robot-assisted spleen preserving pancreatic surgery in MEN1 patients. Journal of Surgical Oncology, 2016, 114, 456-461.	1.7	19
276	Impact of a Nationwide Training Program in Minimally Invasive Distal Pancreatectomy (LAELAPS). Annals of Surgery, 2016, 264, 754-762.	4.2	99
277	Gastric Outlet Obstruction. JAMA Surgery, 2016, 151, 577.	4.3	0
278	Volume–outcome relationships in pancreatoduodenectomy for cancer. Hpb, 2016, 18, 317-324.	0.3	112
279	Postoperative Mortality after Liver Resection for Perihilar Cholangiocarcinoma: Development of a Risk Score and Importance of Biliary Drainage of the Future Liver Remnant. Journal of the American College of Surgeons, 2016, 223, 321-331e1.	0.5	161
280	FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. Lancet Oncology, The, 2016, 17, 801-810.	10.7	719
281	Perihilar Cholangiocarcinoma: Number of Nodes Examined and Optimal Lymph Node Prognostic Scheme. Journal of the American College of Surgeons, 2016, 222, 750-759e2.	0.5	61
282	Intrapancreatic Accessory Spleen Mimicking Pancreatic neoplasm. Journal of Gastrointestinal Surgery, 2016, 20, 2104-2105.	1.7	0
283	Recurrence Patterns and Disease-Free Survival after Resection of Intrahepatic Cholangiocarcinoma: Preoperative and Postoperative Prognostic Models. Journal of the American College of Surgeons, 2016, 223, 493-505e2.	0.5	101
284	A Comparison of Prognostic Schemes for Perihilar Cholangiocarcinoma. Journal of Gastrointestinal Surgery, 2016, 20, 1716-1724.	1.7	31
285	Endoscopic treatment of a refractory intrahepatic bile leak by transpapillary placement of coils into a peripheral bile duct. Gastrointestinal Endoscopy, 2016, 84, 189-190.	1.0	2
286	Resection of Perihilar Cholangiocarcinoma. Surgical Clinics of North America, 2016, 96, 247-267.	1.5	31
287	Observation versus Resection for Small Asymptomatic Pancreatic Neuroendocrine Tumors: A Matched Case–Control Study. Annals of Surgical Oncology, 2016, 23, 1361-1370.	1.5	148
288	Preoperative biliary drainage in perihilar cholangiocarcinoma: identifying patients who require percutaneous drainage after failed endoscopic drainage. Endoscopy, 2015, 47, 1124-1131.	1.8	41

#	Article	IF	CITATIONS
289	The accuracy of pre-operative imaging in the management of hepatic cysts. Hpb, 2015, 17, 889-895.	0.3	16
290	Cytopathological Analysis of Cyst Fluid Enhances Diagnostic Accuracy of Mucinous Pancreatic Cystic Neoplasms. Medicine (United States), 2015, 94, e988.	1.0	7
291	1936 A treatment threshold for decision making in breast cancer surgery for optimal quality of life. European Journal of Cancer, 2015, 51, S310-S311.	2.8	0
292	Resection Margin and Survival in 2368 Patients Undergoing Hepatic Resection for Metastatic Colorectal Cancer. Annals of Surgery, 2015, 262, 476-485.	4.2	156
293	Percutaneous Preoperative Biliary Drainage for Resectable Perihilar Cholangiocarcinoma: No Association with Survival and No Increase in Seeding Metastases. Annals of Surgical Oncology, 2015, 22, 1156-1163.	1.5	44
294	Outcomes after Resection of Intrahepatic Cholangiocarcinoma: External Validation and Comparison of Prognostic Models. Journal of the American College of Surgeons, 2015, 221, 452-461.	0.5	70
295	891 Coil Yourself out of Trouble - an Unusual Solution for an Unusual Problem. Gastrointestinal Endoscopy, 2015, 81, AB178.	1.0	0
296	Diagnostic value of C-reactive protein to rule out infectious complications after major abdominal surgery: a systematic review and meta-analysis. International Journal of Colorectal Disease, 2015, 30, 861-873.	2.2	64
297	Survival after resection of perihilar cholangiocarcinoma—development and external validation of a prognostic nomogram. Annals of Oncology, 2015, 26, 1930-1935.	1.2	103
298	Recurrence Rate and Pattern of Perihilar Cholangiocarcinoma after Curative Intent Resection. Journal of the American College of Surgeons, 2015, 221, 1041-1049.	0.5	143
299	Histological and Molecular Subclassification of Pancreatic and Nonpancreatic Periampullary Cancers: Implications for (Neo) Adjuvant Systemic Treatment. Annals of Surgical Oncology, 2015, 22, 2401-2407.	1.5	10
300	Outcomes in biliary malignancy. Journal of Surgical Oncology, 2014, 110, 585-591.	1.7	78
301	American Joint Committee on Cancer staging for resected perihilar cholangiocarcinoma: a comparison of the 6th and 7th editions. Hpb, 2014, 16, 1074-1082.	0.3	46
302	Prognostic Biomarkers in Patients with Resected Cholangiocarcinoma: A Systematic Review and Meta-analysis. Annals of Surgical Oncology, 2014, 21, 487-500.	1.5	55
303	Patterns of recurrence after resection of gallbladder cancer without routine extrahepatic bile duct resection. Hpb, 2014, 16, 635-640.	0.3	17
304	Differences in immunohistochemical biomarkers between intra―and extrahepatic cholangiocarcinoma: A systematic review and metaâ€analysis . Journal of Gastroenterology and Hepatology (Australia), 2014, 29, 1582-1594.	2.8	38
305	Circulating Tumor Cells and Prognosis of Patients with Resectable Colorectal Liver Metastases or Widespread Metastatic Colorectal Cancer: A Meta-Analysis. Annals of Surgical Oncology, 2013, 20, 2156-2165.	1.5	116
306	Role of Circulating Tumor Cells in Metastatic Colorectal Cancer: Clinical Challenges and Opportunities. Current Colorectal Cancer Reports, 2012, 8, 186-191.	0.5	0

#	Article	IF	CITATIONS
307	The Combined Analysis of Uncertainty and Patient Heterogeneity in Medical Decision Models. Medical Decision Making, 2011, 31, 650-661.	2.4	42
308	Value of Information Analyses of Economic Randomized Controlled Trials: The Treatment of Intermittent Claudication. Value in Health, 2010, 13, 242-250.	0.3	22
309	Uncertainty and Patient Heterogeneity in Medical Decision Models. Medical Decision Making, 2010, 30, 194-205.	2.4	79
310	Cost-effectiveness analysis for surgeons. Surgery, 2009, 145, 616-622.	1.9	15
311	Value of Information Analysis Used to Determine the Necessity of Additional Research: MR Imaging in Acute Knee Trauma as an Example. Radiology, 2008, 246, 420-425.	7.3	32
312	Limitations of Acceptability Curves for Presenting Uncertainty in Cost-Effectiveness Analysis. Medical Decision Making, 2007, 27, 101-111.	2.4	70
313	Identifying key parameters in cost-effectiveness analysis using value of information: a comparison of methods. Health Economics (United Kingdom), 2006, 15, 383-392.	1.7	52
314	GenomicFHIT analysis in RER+ and RER? adenocarcinomas of the pancreas. , 2000, 27, 239-243.		16
315	Novel homozygous deletions of chromosomal band 18q22 in pancreatic adenocarcinoma identified by STS marker scanning. , 1999, 25, 370-375.		9
316	Reply to W. Attaallah, A. Jain et al, and P. Mroczkowski et al. Journal of Clinical Oncology, 0, , .	1.6	1